OTC Healthcare in Spain

Euromonitor International's OTC Healthcare in Spain market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.

Buy online to access strategic market analysis and an interactive statistical database of volume and value market sizes, company and brand shares, distribution and pricing data.

Tables: 128  |  Publication date: Mar 2009
Cost: 
GBP1500.00

Why buy this report

  • Get insight into trends in market performance
  • Pinpoint growth sectors and identify factors driving change
  • Identify market and brand leaders and understand the competitive environment

Product coverage

Adult mouth care; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; OTC triptans; Vitamins and dietary supplements; Wound treatments

Executive summary

OTC products face pressure from semi-ethicals and Rx references

OTC healthcare sales in Spain performed as expected, with no big surprises occurring in 2008. Sales in Spain are shaped by the strong importance of semi-ethical references in some areas such as analgesics or digestive remedies and growing competition from reimbursed Rx references. The latter are especially important as the same active ingredients are sometimes available both OTC and reimbursed.

Financial crisis erodes OTC sales

2008 represented a turning point for the previously healthy Spanish economy with employment, inflation and growth deteriorating rapidly throughout the year. As many economists pointed out the international financial crisis had finally impacted the Spanish economy. One of the primary effects of the economic slowdown in Spain has been a moderation in spending by consumers with modest incomes, especially on non-essential goods.

Concentration in the pipeline

Fragmentation continues to characterise the Spanish OTC market with over 100 companies active, as a result of a high degree of specialisation within sectors. However, concentration is expected to grow over the forecast period as acquisitions take place. At the end of 2007, Johnson & Johnson acquired the Spanish laboratory Abelló Farmacia SL and the consumer healthcare division of Pfizer. It is expected that by 2009 the acquisitions will be completed and the final transfer of portfolios will take place. Furthermore, in 2008 Pierre Fabre acquired the Spanish company Gelos which will also raise the level of concentration.

Manufacturers, distributors and chemists/pharmacies

In Spain, the vast majority of OTC healthcare value sales take place through chemists/pharmacies. As chemists/pharmacies face a high number of restrictions, and as a way of increasing their margins, a large number of chemists/pharmacists have become shareholders of distributors, resulting in a market with a high level of vertical integration. Faced with this challenge, manufacturers are denying selling their products to distributors and instead bypassing this channel altogether by selling their products directly to chemists/pharmacies.

Economic expectations to shape forecast sales

Some economists believe that Spain is heading towards a deep recession exacerbated by a looming housing crash, with an expected 15% rate of unemployment and an unstable inflation rate. The strong pressure exerted on the Spanish public purse, along with the slowdown of economic activity that will result in less tax collected, is expected to force the Government to introduce new measures to save money in areas such as expenditure on medicines. It is expected that a new reference price law will be passed in early 2009 in order to reduce prices of medicines even further. This will result in a fall in average unit prices and hence a slowdown in OTC value sales growth.

Table of contents

OTC HEALTHCARE IN SPAIN : MARKET INSIGHT

EXECUTIVE SUMMARY

OTC products face pressure from semi-ethicals and Rx references

Financial crisis erodes OTC sales

Concentration in the pipeline

Manufacturers, distributors and chemists/pharmacies

Economic expectations to shape forecast sales

KEY TRENDS AND DEVELOPMENTS

Economic crisis drags down Spanish OTC sales

Blurring of distinction between OTC and cosmetics

Manufacturers, distributors and pharmacists want more

Legislation changes on the pipeline

Demographics still an issue

MARKET INDICATORS

Table 1 Consumer Expenditure on Health Goods and Medical Services 2003-2008

Table 2 Life Expectancy at Birth 2003-2008

MARKET DATA

Table 3 Sales of OTC Healthcare by Sector: Value 2003-2008

Table 4 Sales of OTC Healthcare by Sector: % Value Growth 2003-2008

Table 5 OTC Healthcare Company Shares by Value 2004-2008

Table 6 OTC Healthcare Brand Shares by Value 2005-2008

Table 7 Penetration of Private Label by Sector 2003-2008

Table 8 Sales of OTC Healthcare by Distribution Format: % Analysis 2003-2008

Table 9 Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2008

Table 10 Forecast Sales of OTC Healthcare by Sector: Value 2008-2013

Table 11 Forecast Sales of OTC Healthcare by Sector: % Value Growth 2008-2013

APPENDIX

OTC Registration and Classification

Advertising

Packaging and Labelling

Distribution

De-listing or De-reimbursement

Vitamins and Dietary Supplements Registration and Classification

EU Legislation

Self-medication and Preventive Medicine

Generics

Switches

Summary 1 OTC Healthcare Switches 2007-2008

DEFINITIONS

LOCAL COMPANY PROFILES - SPAIN

ALMIRALL PRODESFARMA SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 2 Almirall Prodesfarma SA: Key Facts

Summary 3 Almirall Prodesfarma SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 4 Almirall Prodesfarma SA: Competitive Position 2008

BAYER HISPANIA SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 5 Bayer Hispania SA: Key Facts

Summary 6 Bayer Hispania SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 7 Bayer Hispania SA: Competitive Position 2008

BOEHRINGER INGELHEIM ESPAñA SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 8 Boehringer Ingelheim España SA: Key Facts

Summary 9 Boehringer Ingelheim España SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 10 Boehringer Ingelheim España SA: Competitive Position 2008

ESTEVE SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 11 Esteve SA: Key Facts

Summary 12 Esteve SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 13 Esteve SA: Competitive Position 2008

LABORATORIOS VIñAS SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 14 Laboratorios Viñas SA: Key Facts

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 15 Laboratorios Viñas SA: Competitive Position 2008

MERCK FARMA Y QUíMICA SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 16 Merck Farma y Química SA: Key Facts

Summary 17 Merck Farma y Química SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 18 Merck Farma y Química SA: Competitive Position 2008

NOVARTIS CONSUMER HEALTH SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 19 Novartis Consumer Health SA: Key Facts

Summary 20 Novartis Consumer Health SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 21 Novartis Consumer Health SA: Competitive Position 2008

PFIZER CONSUMER HEALTHCARE SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 22 Pfizer Consumer Healthcare SA: Key Facts

Summary 23 Pfizer Consumer Healthcare SA Operational Indicators

COMPANY BACKGROUND

COMPETITIVE POSITIONING

Summary 24 Pfizer Consumer Healthcare SA: Competitive Position 2008

ROVI SA - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 25 Rovi SA: Key Facts

Summary 26 Rovi SA: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

URIACH-AQUILEA OTC SL - OTC HEALTHCARE - SPAIN

STRATEGIC DIRECTION

KEY FACTS

Summary 27 Uriach-Aquilea OTC SL: Key Facts

Summary 28 Uriach-Aquilea OTC SL: Operational Indicators

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

Summary 29 Uriach-Aquilea OTC SL: Competitive Position 2008

ANALGESICS IN SPAIN

HEADLINES

TRENDS

SWITCHES

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR DATA

Table 12 Sales of Analgesics by Subsector: Value 2003-2008

Table 13 Sales of Analgesics by Subsector: % Value Growth 2003-2008

Table 14 Herbal vs Standard Topical Analgesics 2003-2008

Table 15 Topical Analgesics by Format: % Value Breakdown 2004-2008

Table 16 Analgesics Company Shares by Value 2004-2008

Table 17 Analgesics Brand Shares by Value 2005-2008

Table 18 Forecast Sales of Analgesics by Subsector: Value 2008-2013

Table 19 Forecast Sales of Analgesics by Subsector: % Value Growth 2008-2013

COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES IN SPAIN

HEADLINES

TRENDS

SWITCHES

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR DATA

Table 20 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2003-2008

Table 21 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2003-2008

Table 22 Sales of Decongestants by Type: Value 2003-2008

Table 23 Sales of Decongestants by Type: % Value Growth 2003-2008

Table 24 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: Value 2003-2008

Table 25 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Type: % Value Growth 2003-2008

Table 26 Herbal vs Standard Cough, Cold and Allergy (Hay Fever) Remedies 2003-2008

Table 27 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2004-2008

Table 28 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2005-2008

Table 29 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: Value 2008-2013

Table 30 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Subsector: % Value Growth 2008-2013

DIGESTIVE REMEDIES IN SPAIN

HEADLINES

TRENDS

SWITCHES

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR DATA

Table 31 Sales of Digestive Remedies by Subsector: Value 2003-2008

Table 32 Sales of Digestive Remedies by Subsector: % Value Growth 2003-2008

Table 33 Herbal vs Standard Digestive Remedies 2003-2008

Table 34 Digestive Remedies Company Shares by Value 2004-2008

Table 35 Digestive Remedies Brand Shares by Value 2005-2008

Table 36 Forecast Sales of Digestive Remedies by Subsector: Value 2008-2013

Table 37 Forecast Sales of Digestive Remedies by Subsector: % Value Growth 2008-2013

MEDICATED SKIN CARE IN SPAIN

HEADLINES

TRENDS

SWITCHES

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR DATA

Table 38 Sales of Medicated Skin Care by Subsector: Value 2003-2008

Table 39 Sales of Medicated Skin Care by Subsector: % Value Growth 2003-2008

Table 40 Herbal vs Standard Medicated Skin Care 2003-2008

Table 41 Acne Treatments by Format: % Value Breakdown 2004-2008

Table 42 Medicated Skin Care Company Shares by Value 2004-2008

Table 43 Medicated Skin Care Brand Shares by Value 2005-2008

Table 44 Acne Treatments Brand Shares by Value 2005-2008

Table 45 Hair Loss Treatments Brand Shares by Value 2005-2008

Table 46 Forecast Sales of Medicated Skin Care by Subsector: Value 2008-2013

Table 47 Forecast Sales of Medicated Skin Care by Subsector: % Value Growth 2008-2013

VITAMINS AND DIETARY SUPPLEMENTS IN SPAIN

HEADLINES

TRENDS - VITAMINS

TRENDS – DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR DATA

Summary 30 Dietary Supplements: Brand Ranking by Positioning 2008

Table 48 Sales of Vitamins and Dietary Supplements by Subsector: Value 2003-2008

Table 49 Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2003-2008

Table 50 Folic Acid v Other B Vitamins 2004-2008

Table 51 Dietary Supplements by Positioning 2006-2008

Table 52 Vitamins and Dietary Supplements Company Shares by Value 2004-2008

Table 53 Vitamins and Dietary Supplements Brand Shares by Value 2005-2008

Table 54 Vitamins Brand Shares by Value 2005-2008

Table 55 Dietary Supplements Brand Shares by Value 2005-2008

Table 56 Forecast Sales of Vitamins and Dietary Supplements by Subsector: Value 2008-2013

Table 57 Forecast Sales of Vitamins and Dietary Supplements by Subsector: % Value Growth 2008-2013

NRT SMOKING CESSATION AIDS IN SPAIN

HEADLINES

TRENDS

SWITCHES

COMPETITIVE LANDSCAPE

PROSPECTS

SECTOR INDICATORS

Table 58 Number of Smokers by Gender 2003-2008

Table 59 Sales of Smoking Cessation Aids by Subsector: Value 2003-2008

Table 60 Sales of Smoking Cessation Aids by Subsector: % Value Growth 2003-2008

Table 61 NRT Gum Flavours: % Value Breakdown 2006-2008

Table 62 Smoking Cessation Aids Company Shares by Value 2004-2008

Table 63 Smoking Cessation Aids Brand Shares by Value 2005-2008

Table 64 Forecast Sales of Smoking Cessation Aids by Subsector: Value 2008-2013

Table 65 Forecast Sales of Smoking Cessation Aids by Subsector: % Value Growth 2008-2013

EYE CARE IN SPAIN

TRENDS

SECTOR DATA

Table 66 Sales of Eye Care by Subsector: Value 2003-2008

Table 67 Sales of Eye Care by Subsector: % Value Growth 2003-2008

Table 68 Standard Eye Care by Type: % Value Breakdown 2007-2008

Table 69 Eye Care Company Shares by Value 2004-2008

Table 70 Eye Care Brand Shares by Value 2005-2008

Table 71 Forecast Sales of Eye Care by Subsector: Value 2008-2013

Table 72 Forecast Sales of Eye Care by Subsector: % Value Growth 2008-2013

EAR CARE IN SPAIN

TRENDS

SECTOR DATA

Table 73 Sales of Ear Care: Value 2003-2008

Table 74 Sales of Ear Care: % Value Growth 2003-2008

Table 75 Ear Care Company Shares by Value 2004-2008

Table 76 Ear Care Brand Shares by Value 2005-2008

Table 77 Forecast Sales of Ear Care: Value 2008-2013

Table 78 Forecast Sales of Ear Care: % Value Growth 2008-2013

ADULT MOUTH CARE IN SPAIN

HEADLINES

SECTOR DATA

Table 79 Sales of Adult Mouth Care: Value 2003-2008

Table 80 Sales of Adult Mouth Care: % Value Growth 2003-2008

Table 81 Adult Mouth Care Company Shares by Value 2004-2008

Table 82 Adult Mouth Care Brand Shares by Value 2005-2008

Table 83 Forecast Sales of Adult Mouth Care: Value 2008-2013

Table 84 Forecast Sales of Adult Mouth Care: % Value Growth 2008-2013

CALMING AND SLEEPING PRODUCTS IN SPAIN

TRENDS

SECTOR DATA

Table 85 Sales of Calming and Sleeping Products: Value 2003-2008

Table 86 Sales of Calming and Sleeping Products: % Value Growth 2003-2008

Table 87 Calming and Sleeping Products Company Shares by Value 2004-2008

Table 88 Calming and Sleeping Products Brand Shares by Value 2005-2008

Table 89 Forecast Sales of Calming and Sleeping Products: Value 2008-2013

Table 90 Forecast Sales of Calming and Sleeping Products: % Value Growth 2008-2013

WOUND TREATMENTS IN SPAIN

TRENDS

SECTOR DATA

Table 91 Sales of Wound Treatments by Subsector: Value 2003-2008

Table 92 Sales of Wound Treatments by Subsector: % Value Growth 2003-2008

Table 93 Wound Treatments Company Shares by Value 2004-2008

Table 94 Wound Treatments Brand Shares by Value 2005-2008

Table 95 Forecast Sales of Wound Treatments by Subsector: Value 2008-2013

Table 96 Forecast Sales of Wound Treatments by Subsector: % Value Growth 2008-2013

OTC OBESITY IN SPAIN

TRENDS

SECTOR DATA

Table 97 Forecast Sales of OTC Obesity: Value 2009-2013

Table 98 Forecast Sales of OTC Obesity: % Value Growth 2009-2013